ProQR Therapeutics N.V.
PRQR
$1.47
-$0.06-3.92%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 15.49M | 17.91M | 17.05M | 17.90M | 20.36M |
| Total Other Revenue | 250.50K | 484.10K | 596.50K | 709.60K | 698.20K |
| Total Revenue | 15.74M | 18.40M | 17.64M | 18.61M | 21.06M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 15.74M | 18.40M | 17.64M | 18.61M | 21.06M |
| SG&A Expenses | 18.06M | 17.05M | 16.69M | 16.65M | 14.43M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 69.09M | 67.46M | 66.87M | 64.23M | 56.64M |
| Operating Income | -53.35M | -49.07M | -49.22M | -45.61M | -35.59M |
| Income Before Tax | -52.41M | -47.66M | -47.19M | -43.24M | -32.55M |
| Income Tax Expenses | 21.60K | 21.60K | 20.40K | 20.40K | -215.30K |
| Earnings from Continuing Operations | -52.43 | -47.68 | -47.22 | -43.26 | -32.34 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -52.43M | -47.68M | -47.22M | -43.26M | -32.34M |
| EBIT | -53.35M | -49.07M | -49.22M | -45.61M | -35.59M |
| EBITDA | -50.74M | -46.54M | -46.72M | -43.14M | -33.11M |
| EPS Basic | -0.50 | -0.45 | -0.45 | -0.44 | -0.35 |
| Normalized Basic EPS | -0.31 | -0.28 | -0.28 | -0.28 | -0.22 |
| EPS Diluted | -0.51 | -0.46 | -0.46 | -0.45 | -0.35 |
| Normalized Diluted EPS | -0.31 | -0.28 | -0.28 | -0.28 | -0.22 |
| Average Basic Shares Outstanding | 421.40M | 421.34M | 415.41M | 391.75M | 368.07M |
| Average Diluted Shares Outstanding | 421.40M | 421.34M | 415.41M | 391.75M | 368.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |